Mariner
CORT icon

Mariner’s Corcept Therapeutics CORT Stock Holding History

Mariner’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.81M Buy
89,838
+83,832
+1,396% +$5.06M 0.01% 842
2026
Q1 		$242K Sell
6,006
-13,759
-70% -$514K ﹤0.01% 3042
2025
Q4 		$745K Sell
19,765
-7,975
-29% -$626K ﹤0.01% 2165
2025
Q3 		$2.31M Buy
27,740
+9,068
+49% +$656K ﹤0.01% 1350
2025
Q2 		$1.37M Buy
18,672
+1,455
+8% +$105K ﹤0.01% 1584
2025
Q1 		$1.97M Buy
17,217
+3,855
+29% +$235K ﹤0.01% 1256
2024
Q4 		$673K Buy
13,362
+1,601
+14% +$83.9K ﹤0.01% 1943
2024
Q3 		$542K Sell
11,761
-183
-2% -$6.5K ﹤0.01% 2069
2024
Q2 		$388K Buy
+11,944
New +$327K ﹤0.01% 2249

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mariner's CORT Position: Q2 2026 in Review

Mariner increased its Corcept Therapeutics (CORT) stake by 1,396% in Q2 2026, buying an estimated $5.06M and bringing the position to 89,838 shares worth $7.81M. The position accounts for 0.01% of the portfolio, ranked #842.

Mariner first reported a position in CORT in Q2 2024 and has held it in 9 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Mariner held 89,838 shares of Corcept Therapeutics worth $7.81M as of Q2 2026.
  • Mariner bought 83,832 Corcept Therapeutics shares in Q2 2026, an estimated $5.06M.
  • Corcept Therapeutics made up 0.01% of Mariner's portfolio in Q2 2026, its #842 holding.
  • Mariner first reported a position in Corcept Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.